At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies and unleash the power of myeloid cells in cancer.
Our proprietary ATAK™ platform is designed to provide clinical solutions by matching therapeutic modalities to disease conditions, including by using autologous cell therapies, in vivo cell programming using mRNA, RNA-based gene-editing using RetroT™ and multi-targeted biologics. We have translated the learnings from our backgrounds and our novel platform to create a clinical-stage, mRNA-immunotherapy pipeline focused on breakthrough therapies for cancer and autoimmune diseases.
Myeloid is powered by the discoveries of our founders – a group of world-leading scientists whose expertise spans oncology, immunology, mRNA biology, cell therapy, synthetic biology, and gene delivery.
We’re building a team of talented, driven scientists and other biotech industry experts to turn these discoveries into novel, life-saving treatments for people navigating life with cancer.
SCIENTIFIC ADVISORY BOARD
Immunology, Virology & Myeloid Cell Advisors